MedPath

Comparison of the efficacy of different doses of buprenorphine (8mg, 2mg) on the reduction of methamphetamine(crystal, Shishe) withdrawal symptoms, depression, suicidal thought and anxiety

Not Applicable
Recruiting
Conditions
Methamphetamine Dependency.
Mental and behavioural disorders due to use of other stimulants, including caffeine
Registration Number
IRCT2017081525160N8
Lead Sponsor
Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
66
Inclusion Criteria

Age: 18-60 ;informed consent; methamphetamine dependence Exclusion criteria:Patients unwilling to participate at beginning or during the study; use of another substance except Methamphetamine as of the main substance.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Craving, depression, suicidal thoughts and anxiety. Timepoint: Daily for 5 days. Method of measurement: Questionnaire and interview.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath